serplulimab
fosun pharmaceuticals
['serplulimab']
#asco22 overall survival curves show benefit to adding serplulimab with os hr 0.63, median 15.4m from 10.9m with early and maintained separation of curves. all subgroups performing similarly. high rr with both arms as expected. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him